A detailed history of Peregrine Capital Management LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Peregrine Capital Management LLC holds 41,839 shares of SRPT stock, worth $4.37 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
41,839
Previous 36,294 15.28%
Holding current value
$4.37 Million
Previous $5.73 Million 8.88%
% of portfolio
0.16%
Previous 0.17%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$124.33 - $156.75 $689,409 - $869,178
5,545 Added 15.28%
41,839 $5.23 Million
Q2 2024

Jul 29, 2024

BUY
$113.33 - $163.85 $88,397 - $127,803
780 Added 2.2%
36,294 $5.73 Million
Q1 2024

Apr 26, 2024

SELL
$93.7 - $141.53 $276,321 - $417,371
-2,949 Reduced 7.67%
35,514 $4.6 Million
Q4 2023

Jan 26, 2024

SELL
$67.31 - $124.76 $451,986 - $837,763
-6,715 Reduced 14.86%
38,463 $3.71 Million
Q3 2023

Oct 19, 2023

BUY
$102.5 - $123.59 $529,515 - $638,465
5,166 Added 12.91%
45,178 $5.48 Million
Q2 2023

Jul 26, 2023

SELL
$106.4 - $157.19 $3.25 Million - $4.8 Million
-30,565 Reduced 43.31%
40,012 $4.58 Million
Q1 2023

Apr 26, 2023

BUY
$117.53 - $155.99 $655,347 - $869,800
5,576 Added 8.58%
70,577 $9.73 Million
Q4 2022

Jan 10, 2023

SELL
$100.86 - $132.13 $941,830 - $1.23 Million
-9,338 Reduced 12.56%
65,001 $8.42 Million
Q3 2022

Oct 26, 2022

SELL
$75.71 - $119.24 $1.65 Million - $2.6 Million
-21,825 Reduced 22.7%
74,339 $8.22 Million
Q2 2022

Jul 20, 2022

SELL
$62.69 - $88.44 $4,639 - $6,544
-74 Reduced 0.08%
96,164 $7.21 Million
Q1 2022

Apr 27, 2022

BUY
$63.15 - $90.42 $6.08 Million - $8.7 Million
96,238 New
96,238 $7.52 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.15B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Peregrine Capital Management LLC Portfolio

Follow Peregrine Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.